These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26332194)

  • 1. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
    Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
    NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.
    Barnes SL; Sorace AG; Whisenant JG; McIntyre JO; Kang H; Yankeelov TE
    NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28915312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
    Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
    Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of dynamic contrast-enhanced MRI and diffusion-weighted MRI in patients with maxillofacial tumors.
    Kitamoto E; Chikui T; Kawano S; Ohga M; Kobayashi K; Matsuo Y; Yoshiura T; Obara M; Honda H; Yoshiura K
    Acad Radiol; 2015 Feb; 22(2):210-6. PubMed ID: 25442795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Pancreatic Cancer: Characteristics and Correlation With Histopathologic Parameters.
    Ma W; Li N; Zhao W; Ren J; Wei M; Yang Y; Wang Y; Fu X; Zhang Z; Larson AC; Huan Y
    J Comput Assist Tomogr; 2016; 40(5):709-16. PubMed ID: 27224231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfusion Parameters in Dynamic Contrast-enhanced MRI and Apparent Diffusion Coefficient Value in Diffusion-weighted MRI:: Association with Prognostic Factors in Breast Cancer.
    Lee HS; Kim SH; Kang BJ; Baek JE; Song BJ
    Acad Radiol; 2016 Apr; 23(4):446-56. PubMed ID: 26852247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
    Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
    Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
    Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
    AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the relationship between the apparent diffusion coefficient and extravascular extracellular volume fraction in human breast cancer.
    Arlinghaus LR; Li X; Rahman AR; Welch EB; Xu L; Gore JC; Yankeelov TE
    Magn Reson Imaging; 2011 Jun; 29(5):630-8. PubMed ID: 21531106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.
    Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts.
    Whisenant JG; Sorace AG; McIntyre JO; Kang H; Sánchez V; Loveless ME; Yankeelov TE
    Transl Oncol; 2014 Dec; 7(6):768-79. PubMed ID: 25500087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
    Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted imaging: Effects of intravascular contrast agents on apparent diffusion coefficient measures of breast malignancies at 3 Tesla.
    Nguyen VT; Rahbar H; Olson ML; Liu CL; Lehman CD; Partridge SC
    J Magn Reson Imaging; 2015 Sep; 42(3):788-800. PubMed ID: 25611726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
    Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
    Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
    Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
    Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI.
    Hompland T; Ellingsen C; Galappathi K; Rofstad EK
    Acta Oncol; 2014 Jan; 53(1):6-15. PubMed ID: 23445339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.